Quick Start
- Identity
- Small-molecule NNMT inhibitor
- Primary format
- 10 mg lyophilized research vial
- Default route
- SubQ research calculation
- Human evidence
- No administration trials located
- Evidence
- Laboratory and animal research
- Status
- Investigational; not FDA-approved
Dosing Protocol and Schedule
Choose the timing fields and enter the amount in the calculator. No human SubQ schedule is prefilled.
Enter a target amount and frequency below to populate the schedule.
Supplies Needed
Research vial
Verified 10 mg lyophilized presentation
Documented diluent
Exact type and volume recorded by the laboratory
Calibrated equipment
Volume-measuring equipment appropriate to the work
Study record
Lot, preparation, calculation, and observation notes
Reconstitution Calculator
Advanced options
Enter a target amount to calculate the vial arithmetic.
Live U-100 syringe
— units
100 U-100 units = 1 mL.
Best Time
No evidence-based time of day is established
The reviewed animal studies report study schedules, but they do not establish a best administration time for humans. Use the schedule tool only to organize a research record.
Oral vs Injection
SubQ research discussion
Subcutaneous administration appears in published animal research. The 10 mg vial calculator above is a user-entered laboratory arithmetic tool and does not establish a human protocol.
Half-Life and Frequency
- Human half-life
- Not established in verified research
- Human frequency
- Not established; calculator frequency is user selected
Dosage Chart
| Evidence context | Model | Route | Amount reported | Frequency | Duration |
|---|---|---|---|---|---|
| Preclinical animal | Mouse | Subcutaneous | 20 mg/kg | Three administrations daily | 11 days |
| Preclinical animal | Mouse | Subcutaneous | 32 mg/kg | Once daily | Approximately 7 weeks |
| Preclinical animal | Mouse | Subcutaneous | 10 mg/kg | Once daily | Approximately 28–30 days |
| Preclinical animal | Aged mouse | Subcutaneous | 5 mg/kg | Twice daily | Approximately 2 weeks around the injury experiment |
Animal-study rows are kept separate from user-entered SubQ vial calculations and are not human-equivalent amounts.
Reconstitution Guide
1Verify the material
Confirm identity, strength, seal integrity, and manufacturer documentation before calculating.
2Prepare the workspace
Use the controlled process and supplies required by the laboratory.
3Record the diluent volume
Enter the exact volume used so concentration can be calculated.
4Follow the product documentation
Use the manufacturer's written handling method rather than substituting a generic method.
5Inspect the solution
Appearance alone cannot confirm identity or sterility.
6Read the calculation
Use the calculated mL and U-100 units only for the values entered.
7Label the record
Document preparation date, concentration, lot information, and storage instructions.
8Stop for visible changes
Unexpected cloudiness, particles, discoloration, or container damage requires review.
How It Works
NNMT
An enzyme that uses nicotinamide.
Nicotinamide availability
Inhibition changes how nicotinamide is handled.
NAD+ and metabolism
Preclinical models observed downstream metabolic changes.
Human Trials and FDA Status
Human trials
No verified published human administration trial was identified in the reviewed record. Current evidence is laboratory and animal based.
FDA status
5-Amino-1MQ is investigational and is not represented here as FDA-approved for a clinical use.
Who Should Avoid It
Human safety has not been established. The reviewed record does not support use in pregnancy, breastfeeding, children, people with significant medical conditions, or alongside medications without qualified clinical review.
Side Effects and Safety
Read safety details
pregnancy: No reproductive or developmental safety data were identified in any species.
unknown: No controlled human safety study was identified, so no human adverse-event rate can be quantified for any amount or route.
unknown: Long-term exposure has not been studied in any species beyond the published short animal protocols (11 days to about 7 weeks).
unknown: NNMT inhibition alters nicotinamide and methyl-group handling. Downstream effects of sustained inhibition in people have not been measured.
unknown: Community-sourced oral capsules are not verified for identity, purity or amount, so the exposure a person actually receives is unknown.
Timeline and Monitoring
This timeline shows research observation points—not personal expected results.
Baseline — diet-induced obesity established
Before first administration · Mice were made obese on a high-fat diet and baseline body composition was recorded.
Benefits and Results
Potential areas studied in preclinical models
- Body weight and adiposity measures in diet-induced obese mice.
- Metabolic measures and microbiome composition in a reduced-calorie mouse model.
- Muscle stem-cell and regenerative-capacity research in aged mice.
- Cellular pathways related to NNMT inhibition and nicotinamide metabolism.
Storage and Handling
Troubleshooting
The result looks too large
Confirm that amount units, vial strength, and water volume were entered correctly.
The syringe exceeds capacity
The calculator flags a result above the selected U-100 capacity; review the entered values.
The solution looks different
Cloudiness, particles, discoloration, or container damage requires product-specific review.
The routes do not match
Keep oral reports and SubQ animal research separate; no conversion is provided.
Comparisons
| Compound | Mechanism | Route | Appetite effect | Evidence level | Regulatory status |
|---|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition | SubQ animal studies; oral community reports | Not established in humans | Preclinical | Not FDA-approved |
| Semaglutide | GLP-1 receptor agonist | Subcutaneous or oral medication | Appetite reduction established | Controlled human trials | FDA-approved for specific indications |
FAQ
Is 5-Amino-1MQ a peptide?
No. 5-amino-1-methylquinolinium is a small molecule that inhibits nicotinamide N-methyltransferase (NNMT). It is grouped with peptide-adjacent metabolic research compounds, which is why it appears in this catalog.
Has 5-Amino-1MQ been studied in people?
No published human administration study was identified. Every protocol on this page comes from mouse research or from unverified community reports.
Why do the reported amounts differ between studies?
The 2018 work reports 20 mg/kg per injection three times daily as the tested salt preparation, which corresponds to roughly 34 mg/kg/day of active parent compound. Other studies used once-daily or twice-daily schedules, different durations and different research questions. Both salt-weight and parent-weight figures are preserved rather than merged.
Can the animal amounts be converted into a human amount?
No. This page never converts animal amounts into human amounts. Species differences in metabolism, route and exposure make that conversion unsupported.
Does 5-Amino-1MQ need to be mixed with bacteriostatic water?
No. It is recorded as an oral small molecule, so mixing, syringe and injection tools are not shown on this page. The subcutaneous route appears only in animal research.
Is there an established cycle or rest period?
No. No published study tested a required rest or washout period, so no evidence-based rest period has been established.
References
- 1Source
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Biochemical Pharmacology · 2018 · Preclinical animal study
- 2Source
Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
Scientific Reports · 2022 · Preclinical animal study
- 3Source
Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
Diabetes, Obesity and Metabolism · 2024 · Preclinical animal study
Educational research reference only. Calculations use visitor-entered values and do not establish a human dose, treatment, route conversion, cycle, or restart interval.